Aileron Therapeutics (ALRN) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate ALRN-6924 in Combination with IBRANCE (palbociclib) in MDM2-Amplified Cancers

November 27, 2018 8:05 AM
Aileron Therapeutics (NASDAQ: ALRN) today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles